Search research articles
Contact Us
Filters
Showing results (251-260 of 263) with videos related to
Page
of 27
Sort By:
Antiviral Therapy
|
July 19, 2005
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
E Negredo, R Paredes, A Bonjoch, et al.
HIV Medicine
|
December 23, 2017
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort
A Roen, K Laut, A Pelchen-Matthews, et al.
AIDS Research and Human Retroviruses
|
June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients
K Van Laethem, J C Schmit, H Pelemans, et al.
The Lancet. Infectious Diseases
|
March 25, 2011
European guidelines on the clinical management of HIV-1 tropism testing
L P R Vandekerckhove, A M J Wensing, R Kaiser, et al.
HIV Medicine
|
January 15, 2015
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data
J Vingerhoets, V Calvez, P Flandre, et al.
The Journal of Antimicrobial Chemotherapy
|
May 17, 2014
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients
D Podzamczer, A Imaz, I Perez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
June 29, 2001
[GESIDA Consensus document on the use of resistance studies in clinical practice]
J M Gatell, J L Blanco, J Alcamí, et al.
Antimicrobial Agents and Chemotherapy
|
July 18, 2000
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
K Van Vaerenbergh, K Van Laethem, J Albert, et al.
Vaccine
|
August 7, 2004
Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects
E Fernandez-Cruz, S Moreno, J Navarro, et al.
The Journal of Antimicrobial Chemotherapy
|
July 19, 2015
Primary resistance to integrase strand-transfer inhibitors in Europe
M Casadellà, P M van Ham, M Noguera-Julian, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 263) with videos related to
Sort By:
Page
of 27
Antiviral Therapy
|
July 19, 2005
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up
E Negredo, R Paredes, A Bonjoch, et al.
HIV Medicine
|
December 23, 2017
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort
A Roen, K Laut, A Pelchen-Matthews, et al.
AIDS Research and Human Retroviruses
|
June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients
K Van Laethem, J C Schmit, H Pelemans, et al.
The Lancet. Infectious Diseases
|
March 25, 2011
European guidelines on the clinical management of HIV-1 tropism testing
L P R Vandekerckhove, A M J Wensing, R Kaiser, et al.
HIV Medicine
|
January 15, 2015
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data
J Vingerhoets, V Calvez, P Flandre, et al.
The Journal of Antimicrobial Chemotherapy
|
May 17, 2014
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients
D Podzamczer, A Imaz, I Perez, et al.
Enfermedades Infecciosas Y Microbiologia Clinica
|
June 29, 2001
[GESIDA Consensus document on the use of resistance studies in clinical practice]
J M Gatell, J L Blanco, J Alcamí, et al.
Antimicrobial Agents and Chemotherapy
|
July 18, 2000
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
K Van Vaerenbergh, K Van Laethem, J Albert, et al.
Vaccine
|
August 7, 2004
Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects
E Fernandez-Cruz, S Moreno, J Navarro, et al.
The Journal of Antimicrobial Chemotherapy
|
July 19, 2015
Primary resistance to integrase strand-transfer inhibitors in Europe
M Casadellà, P M van Ham, M Noguera-Julian, et al.
Page
of 27